More data on airway hyperresponsiveness are still needed for anti-IL-5 therapy, but a recent phase 4 clinical trial revealed reduced airway hyperresponsiveness in patients with severe eosinophilic asthma treated with benralizumab [93]. The gene discussed is IL5; the disease is airway hyperresponsiveness.